Bioregenx (BRGX) Common Equity (2021 - 2026)

Bioregenx's Common Equity history runs 6 years deep, the most recent figure standing at -$4.5 million for Q1 2026.

• In Q1 2026, Common Equity fell 27.38% year-over-year to -$4.5 million; the TTM figure through Mar 2026 stood at -$4.5 million (down 27.38% YoY), while the FY2025 annual figure was -$4.5 million, down 34.27% from the prior year.
• Common Equity was -$4.5 million for Q1 2026 at Bioregenx, roughly flat from -$4.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $15.1 million in Q1 2024 to a low of -$4.5 million in Q4 2025.
• Historically, Common Equity has averaged $391273.8 across 5 years, with a median of -$2.5 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Common Equity tumbled 2901.09% in 2022, then soared 724.59% in 2024.
• A 5-year view of Common Equity shows it stood at -$2.5 million in 2022, then increased by 18.06% to -$2.1 million in 2023, then tumbled by 63.14% to -$3.4 million in 2024, then tumbled by 34.27% to -$4.5 million in 2025, then rose by 0.09% to -$4.5 million in 2026.
• The last three Common Equity figures came in at -$4.5 million (Q1 2026), -$4.5 million (Q4 2025), and -$3.6 million (Q3 2025), per Business Quant data.